Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Read More
Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL
The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.
Read More
Anti-CD20 Regimens and Triplet Therapies in CLL
Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
Read More
Considerations for COVID-19 in MCL and CLL
Focusing the discussion on the current state of the COVID-19 pandemic, Catherine C. Coombs, MD, shares key insights into the use of COVID-19 pre-exposure prevention for patients with CLL or MCL.
Read More
The Potential Role of Venetoclax Combination Approaches in CLL
Experts in hematologic malignancies reflect on clinical trials studying venetoclax combination approaches including the CAPTIVATE, FLAIR, GLOW, VISION, SEQUOIA, and MAJIC studies.
Read More
TRANSCEND CLL: CAR T-cell Therapy for CLL
Panelists respond to a question from Michael Wang, MD, about the role of CAR T-cell therapy in CLL, and Brian T. Hill, MD, PhD, summarizes takeaways from the TRANSCEND CLL study.
Read More
Brian T. Hill, MD, PhD, and Matthew S. Davids, MD, MMSc, address the role of study design in CLL to highlight the importance of patient-reported QOL outcomes and matching-adjusted indirect treatment comparisons (MAICs).
Read More
Treatment Decision-making Among Second-generation BTKis in CLL
Key opinion leaders in CLL review factors driving therapeutic decision-making among the available second-generation BTK inhibitors including efficacy and safety considerations.
Read More
Zanubrutinib in CLL: The ALPINE Trial
An expert in hematologic malignancies, Catherine C. Coombs, MD, shares insights gleaned from the ALPINE clinical trial of zanubrutinib vs ibrutinib for relapsed/refractory CLL.
Read More
Acalabrutinib in CLL: Insights from the ELEVATE TN and ASCEND Trials
Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.
Read More
Treatment Overview: Chronic Lymphocytic Leukemia
Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.
Read More
Advancements on the Horizon in Mantle Cell Lymphoma
Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.
Read More
Strategies for Sequencing and Combining Therapies in MCL
A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.
Read More
Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.
Read More
BTK Inhibitors in Relapsed/Refractory MCL and Treatment Selection
Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.
Read More
Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
Read More
Mantle Cell Lymphoma Maintenance Strategies
A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.
Read More
Factors for Consideration in Treatment Decision-making for MCL
Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.
Read More
Disease Overview: Mantle Cell Lymphoma
Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.
Read More
Optimizing the Treatment of CLL With Novel Therapies
Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Read More
Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax
Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.
Read More
Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab
The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.
Read More
Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Read More